In the race to develop a coronavirus treatment, Regeneron thinks it has the inside track
TARRYTOWN, N.Y. — The novel coronavirus arrived at Regeneron Pharmaceuticals’ sprawling campus like any other parcel.
Inside a cardboard box, shipped to the company’s scientists, was a small tube. And inside it was a fragment of genetic code belonging to 2019-nCoV, the infectious agent that has killed more than 400 people since the start of the outbreak in China. Because it was just a snippet of the full genome, the virus wasn’t actually infectious.
